Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
AZD4573
Description:
An experimental selective inhibitor of cyclin-dependent kinase 9, investigated for its effects on cancer-cell survival and gene transcription.
Primary topic:
Lymphoma Diagnosis and Treatment (23%)
Related topics:
Lymphoma Diagnosis and Treatment (23%),
Cancer-related Molecular Pathways (11%),
Cell death mechanisms and regulation (8%)
OpenAlex ID:
keywords/azd4573
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
2020
·
Justin Cidado
, Scott Boiko
, et al.
·
Clinical Cancer Research
·
316
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition
2020
·
Bing Z. Carter
, Po Yee Mak
, et al.
·
Haematologica
·
138
PDF
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
2020
·
Bernard Barlaam
, Robert Casella
, et al.
·
Journal of Medicinal Chemistry
·
134
CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma
2023
·
Elana Thieme
, Nur Bruss
, et al.
·
Molecular Cancer
·
49
PDF
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas
2020
·
Scott Boiko
, Theresa Proia
, et al.
·
Blood
·
40
Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors
2020
·
Thomas Robert
, Jared L. Johnson
, et al.
·
Frontiers in Chemistry
·
31
PDF
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
2023
·
Arany Soosainathan
, Marjan Iravani
, et al.
·
Cancer Research
·
25
PDF
Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
2020
·
Su-Lin Lim
, Liang Xu
, et al.
·
PLoS ONE
·
22
PDF
A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies
2020
·
Clara Alcon
, Albert Manzano-Muñoz
, et al.
·
Clinical Cancer Research
·
17
PDF
Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation
2022
·
Paolo Strati
, Tae Min Kim
, et al.
·
Blood
·
13
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study
2022
·
Tim H. Brummendorf
, Patrick Medd
, et al.
·
Blood
·
12
From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations
2021
·
Staffan Karlsson
, Helen Benson
, et al.
·
Organic Process Research & Development
·
11
Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies
2018
·
Bernard Barlaam
, Chris De Savi
, et al.
·
Cancer Research
·
11
Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1
2018
·
Justin Cidado
, Theresa Proia
, et al.
·
Cancer Research
·
10
A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.
2018
·
Simon Rule
, Arnon P. Kater
, et al.
·
Journal of Clinical Oncology
·
10
Proteomics and phosphoproteomics of chordoma biopsies reveal alterations in multiple pathways and aberrant kinases activities
2022
·
Jing Hang
, Hanqiang Ouyang
, et al.
·
Frontiers in Oncology
·
8
PDF
Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma
2022
·
Yu-Yun Shao
, Hung-Wei Hsu
, et al.
·
Oncology
·
8
Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions
2018
·
Bing Z Carter
, Po Yee Mak
, et al.
·
Blood
·
6
Cyclin dependent kinase 9 inhibitor induces transcription-replication conflicts and DNA damage accumulation in breast cancer
2025
·
Minyoung Lee
, Kyung-Hun Lee
, et al.
·
Cancer Cell International
·
5
PDF
P1126: Phase 1b/2a Study of Azd4573 (cdk9i) and Acalabrutinib in Patients (pts) With Relapsed/refractory Diffuse Large B-cell Lymphoma (r/r Dlbcl)
2023
·
Paolo Strati
, Franck Morschhauser
, et al.
·
HemaSphere
·
5
Abstract 306: A mechanistic rationale for combining acalabrutinib with CDK9 inhibitor, AZD4573, in ABC-DLBCL
2018
·
Scott Boiko
, Theresa Proia
, et al.
·
Cancer Research
·
5
Cyclin dependent kinase 9 inhibition reduced programmed death-ligand 1 expression and improved treatment efficacy in hepatocellular carcinoma
2024
·
Yu-Yun Shao
, Min-Shu Hsieh
, et al.
·
Heliyon
·
4
PDF
Suppression of microtubule acetylation mediates the anti-leukemic effect of CDK9 inhibition
2024
·
Xi Xie
, Baoyuan Zhang
, et al.
·
Cancer Cell International
·
3
PDF
AZD4573 in Combination with CHOP Increases Combination Benefit in Preclinical Peripheral T-Cell Lymphomas Models
2023
·
Danielle S Potter
, India Ott
, et al.
·
Blood
·
3
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis
2023
·
P. L. Zinzani
, T. Feldman
, et al.
·
Hematological Oncology
·
3
PDF
Show more works
View as search
Works count:
119
Citation count:
920
Year
Topic
Type